Pharmaceutical and Biotech Sector Still Overvalued, Exercise Caution in Investment
Jump to 0:56Manager Park Byung-joo assessed that the pharmaceutical and biotech sector remains overvalued. He believes that the sector will struggle to act as a market leader until next year and expressed skepticism about 'all-in' investments in the overall portfolio.
He added that while the pharmaceutical and biotech sector might see short-term surges, it is more likely to be a temporary phenomenon rather than sustained trend-driven growth.


